Quick Answer
Bluejay Diagnostics, Inc. reported Cash and Equivalents of $5.16 million for fiscal year 2025.
Bluejay Diagnostics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $5.16M | +20.1% |
| 2024 | $4.30M | +94.8% |
| 2023 | $2.21M | -78.2% |
| 2022 | $10.11M | -46.9% |
| 2021 | $19.05M | +1987.7% |
| 2020 | $912.4K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.08M | -46.4% | -30.6% |
| June 30, 2025 | $4.44M | -44.9% | +42.6% |
| March 31, 2025 | $3.12M | +17.1% | -27.6% |
| December 31, 2024 | $4.30M | +94.8% | -25.3% |
| September 30, 2024 | $5.76M | +13.4% | -28.6% |
| June 30, 2024 | $8.06M | +58.0% | +202.8% |
| March 31, 2024 | $2.66M | -60.8% | +20.5% |
| December 31, 2023 | $2.21M | -78.2% | -56.5% |
- Bluejay Diagnostics, Inc. showed an increase of +20.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Bluejay Diagnostics, Inc.’s cash and equivalents has grown by 466.1% (from $912.4 thousand to $5.16 million).
- The most recent figure is from Bluejay Diagnostics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: